← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA519.6x23.4x40.3x
EV / LTM revenue83.5x5.2x7.8x
Premium to unaffected price524%42%66%
Premium to 30-day VWAP3Too thin to quote. Widen the cut.

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
015292009: 1 deals, 0 clean on every measure200912010: 26 deals, 4 clean on every measure2010262011: 20 deals, 11 clean on every measure2011202012: 19 deals, 15 clean on every measure2012192013: 15 deals, 13 clean on every measure2013152014: 13 deals, 12 clean on every measure2014132015: 14 deals, 13 clean on every measure2015142016: 11 deals, 11 clean on every measure2016112017: 20 deals, 20 clean on every measure2017202018: 14 deals, 10 clean on every measure2018142019: 7 deals, 6 clean on every measure201972020: 11 deals, 9 clean on every measure2020112021: 21 deals, 17 clean on every measure2021212022: 22 deals, 21 clean on every measure2022222023: 29 deals, 19 clean on every measure2023292024: 24 deals, 18 clean on every measure2024242025: 29 deals, 24 clean on every measure2025292026: 19 deals, 14 clean on every measure202619
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 23.4x median across 5 dealsHealthcare23.4xn=5Business Services: 16.9x median across 4 dealsBusiness Services16.9xn=4Technology: 16.0x median across 9 dealsTechnology16.0xn=9Utilities: 11.9x median across 4 dealsUtilities11.9xn=4Consumer & Retail: 8.5x median across 6 dealsConsumer & Retail8.5xn=6
Deals by sector
Technology: 21 dealsTechnology21Consumer & Retail: 12 dealsConsumer & Retail12Healthcare: 11 dealsHealthcare11Financials: 8 dealsFinancials8Industrials: 7 dealsIndustrials7Utilities: 7 dealsUtilities7Business Services: 5 dealsBusiness Services5Real Estate: 5 dealsReal Estate5Materials: 4 dealsMaterials4Energy: 3 dealsEnergy3Media & Telecom: 3 dealsMedia & Telecom3Other: 1 dealsOther1
Deals by buyer type
Financial sponsor: 1 dealsFinancial sponsor1Strategic: 7 dealsStrategic7Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 2 dealsUnclassified2
Deals by enterprise value
Under $250m: 3 dealsUnder $250m3$250m to $1bn: 3 deals$250m to $1bn3$1bn to $5bn: 4 deals$1bn to $5bn4$5bn to $20bn: 1 deals$5bn to $20bn1Over $20bn: 0 dealsOver $20bn0Not computed: 0 dealsNot computed0
Deals by industry code
Chemicals, Pharmaceuticals & Allied Products: 6 dealsChemicals, Pharmaceutic…6Instruments, Medical Devices & Optical Goods: 4 dealsInstruments, Medical De…4Health Services: 1 dealsHealth Services1
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
China Biologic Products Holdings, Inc.
2020-11-19 · Take-private · $120.00 a share
Centurium Capital Partners 2018, L.P.
Strategic
Healthcare$4.5bn23.4x8.8x
n.a.
SC 13E3
All cash
Urovant Sciences Ltd.
2020-11-12 · Take-private · $16.25 a share
Board book on file →
Sumitomo Dainippon Pharma Co., LTD.
Strategic
Healthcare$611mn.a.n.a.
96%
92% to VWAP
SC 13E3
All cash
Reliv International Inc
2020-10-22 (filed) · Take-private · $3.75 a share
Not named in the filing
Controlling holder
Healthcare$5m15.0x0.1x
n.a.
SC 13E3
All cash
American Renal Associates Holdings, Inc.
2020-10-01 · Public merger · $11.50 a share
IRC Superman Midco, LLC, LLC
Unclassified
Healthcare$842mn.a.1.0x
66%
DEFM14A
All cash
Akcea Therapeutics, Inc.
2020-08-30 · Take-private · $18.15 a share
Board book on file →
Ionis Pharmaceuticals Inc
Strategic
Healthcare$1.5bnn.a.4.3x
42%
55% to VWAP
SC 13E3
All cash
Cellular Biomedicine Group, Inc.
2020-08-11 · Take-private · $19.75 a share
Held out of the multiples: EV / LTM revenue 1299.0x above 60x
Board book on file →
CBMG Holdings
Strategic
Healthcare$390mn.a.1299.0x
12%
SC 13E3
All cash
Varian Medical Systems Inc
2020-08-02 · Public merger · $177.50 a share
Falcon Sub Inc.
Strategic
Healthcare$16bn40.3x5.0x
24%
DEFM14A
All cash
Liquidia Technologies Inc
2020-06-29 · Public merger · $4.77 a share
PBM RG Holdings, LLC
Strategic
Healthcare$110mn.a.13.5x
n.a.
DEFM14A
All cash
TearLab Corp
2020-05-11 · Public merger · $0.06 a share
Held out of the multiples: EV / LTM EBITDA 95.9x outside 1x to 75x
Accelmed Partners II LP
Financial sponsor
Healthcare$77m95.9x3.5x
n.a.
DEFM14C
All cash
Wright Medical Group N.V.
2020-03-20 (filed) · Public merger · $30.75 a share
Not named in the filing
Unclassified
Healthcare$5.0bn65.5x5.4x
n.a.
50% to VWAP
DEFM14A
All cash
China Biologic Products Holdings, Inc.
2020-02-19 (filed) · Take-private · $101.00 a share
Board book on file →
Centurium Capital Partners 2018, L.P.
Strategic
Healthcare$3.7bn19.6x7.4x
n.a.
SC 13E3
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More